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Abstract Interferon-K (IFN-K) treatment can suppress the
hypersecretion syndrome associated with functional neuroendo-
crine tumors. Chromogranin A (CgA) is a matrix protein of
neuroendocrine secretory vesicles and appears to be essential for
an appropriate neuroendocrine secretory function. To test the
hypothesis that IFN-K can directly interfere with CgA gene
transcription, we performed transient transfection studies in
pancreatic neuroendocrine tumor cells employing CgA-luciferase
reporter gene constructs showing that IFN-K inhibited basal and
protein kinase C-dependent CgA promoter activity. Using 5P-
deletion constructs in combination with mutational analysis of
the proximal CgA core promoter, a cyclic AMP response
element (CRE) at 371 to 364 bp was identified as the IFN-K
response element of the CgA gene. Furthermore, functional
studies indicated that IFN-K exerts its effect on the CgA
promoter via interference with CRE binding protein (CREB)/
CREB binding protein (CBP)-dependent transactivation of the
CgA-CRE.
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1. Introduction
Patients with metastatic gastroenteropancreatic neuroendo-
crine tumor (NET) disease present with symptoms of a tumor-
related hypersecretion syndrome, which is characterized by
£ushing, diarrhea, bronchial constriction and occasionally
valvular heart disease and hypertension [1]. These symptoms
are caused by bioactive molecules comprising regulatory pep-
tides, serotonin and tachykinins, which are produced and se-
creted by neuroendocrine tumor cells [2]. Biotherapy with in-
terferon-K (IFN-K) represents an established concept for the
treatment of the hypersecretion syndrome, featuring less seri-
ous side e¡ects than systemic chemotherapy [3^7]. Clinical
studies demonstrated that IFN-K therapy can decrease expres-
sion of neuroendocrine tumor secretory products and that this
e¡ect depends on interference with pre-translational mecha-
nisms of gene regulation [3,8]. In this context, chromogranin
A (CgA), an essential matrix protein of neuroendocrine secre-
tory granules, has been identi¢ed as a cellular target of IFN-K
[3,8]. CgA is critically involved in the formation and conden-
sation of secretory granules of neuroendocrine cells and in
vitro studies demonstrated that diminished cellular CgA levels
might result in perturbation of secretory functions [9^11]. In
addition, molecular analysis of mouse CgA (mCgA) and hu-
man CgA genes revealed that a cAMP-responsive element
binding protein (CREB) recognition motif located in the
highly conserved proximal CgA core promoter is crucial for
neuroendocrine-speci¢c as well as regulated CgA gene expres-
sion [11^14]. Since direct interference with CgA transcription
could represent a potential mechanism underlying the inhib-
itory action of IFN-K on the NET-associated hypersecretion
syndrome, we investigated the e¡ect of IFN-K on the tran-
scriptional activity of the CgA promoter in human pancreatic
neuroendocrine tumor cells.
2. Materials and methods
2.1. Cell culture and transfection studies
BON neuroendocrine pancreatic carcinoma cells were grown in
Dulbecco’s modi¢ed Eagle’s medium (Life Technologies, Karlsruhe,
Germany) containing 10% fetal calf serum (Biochrom, Berlin, Ger-
many), 100 IU/ml penicillin and 100 IU/ml streptomycin in a humidi-
¢ed atmosphere of 5% CO2 and 95% air at 37‡C. Transient trans-
fections of cultured BON cells were carried out using the calcium
phosphate precipitation technique (DNA transfection kit, 5PPrime
3PPrime, Boulder, CO, USA) as previously described [12]. In brief,
cells were plated at a density of 4U105 cells/35 mm well and trans-
fected with 1 Wg of plasmid DNA per well. Following two washes with
phosphate-bu¡ered saline, medium was replaced by serum-free me-
dium (Ultraculture, BioWhittaker, Walkersville, MA, USA). After
treatment with IFN-K (Roche, Basel, Switzerland) and/or phorbol
12-myristate 13-acetate (PMA) (Sigma, Deisenhofen, Germany) for
24 h, cells were harvested and extracts were analyzed for luciferase
(Luc) activity using the Luc assay system (Promega, Madison, WI,
USA). Luc activity was measured using a Lumat LB 9501 luminom-
eter (Berthold, Bad Wildbad, Germany). Light production was ex-
pressed as relative light units (RLU). Transfections were done in
triplicates or quadruplicates and results were calculated as mean þ
S.E.M. Values for mCgA-Luc activities were expressed as the fold
increase compared to untreated controls. Co-transfection of a L-ga-
lactosidase expression construct (Promega, Madison, WI, USA) was
used to correct transfections for intra-assay variance. In general, in-
tra-assay variance between single determinations did not exceed 10^
15%.
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2.2. Plasmids
mCgA 5P-deletion constructs used in this study were based on the
promoterless Luc reporter gene vector pXP1 and have been previously
described [11]. Mutants of the mCgA-cyclic AMP-responsive element
(CRE) were prepared by a PCR-based approach using the pXP100
construct as a template, employing di¡erent mutated 5P-oligonucleo-
tide primers and a common 3P-primer [11]. The correctness of PCR
inserts in all constructs was con¢rmed by dideoxy sequencing. To
study the characteristics of the in£uence of IFN-K on the mCgA-
CRE in a heterologous promoter system, we used a construct in which
the region mCgA 369 to 362 bp was subcloned upstream of the
enhancerless herpes simplex thymidine kinase (TK) viral promoter
into the plasmid pTK-Luc [11]. Vectors encoding the viral oncopro-
tein E1A and the CREB co-activator protein CREB binding protein
(CBP) have been previously described [15,16]. Phosphorylated CREB
(pCREB) was generated by co-transfection of plasmids containing
cDNAs for CREB and an activated form of protein kinase A
(PKA) subunit K as previously described [12]. The characteristics of
the protein kinase C (PKC)-K overexpression construct used in this
study have been reported before [17].
3. Results
3.1. IFN-K dose-dependently inhibits basal and PKC-stimulated
mCgA promoter activity
In BON cells transfected with the mCgA4.8kb-Luc con-
struct, IFN-K dose-dependently inhibited basal mCgA pro-
moter activity, showing a detectable inhibition at 10 IU/ml
and maximal inhibition at 1000 IU/ml (Fig. 1A). A further
increase of IFN-K concentrations did not produce stronger
inhibition of mCgA promoter activity (data not shown). Ac-
tivation of PKC-K-dependent signaling pathways by phorbol-
ester (PMA) treatment potently transactivated the mCgA
promoter in BON cells (Fig. 1B). Similarly, overexpression
of PKC-K resulted in a 3^4-fold elevation of mCgA4.8kb-
Luc activity (Fig. 1B). IFN-K treatment dose-dependently in-
hibited PMA-stimulated mCgA promoter activity showing a
maximal e¡ect of approximately 50% inhibition at 1000 IU/ml
(Fig. 1B).
3.2. 5P-Deletion analysis of the IFN-K-sensitive region of the
mCgA promoter
To de¢ne the IFN-K-sensitive region of the mCgA pro-
moter, various mCgA-Luc 5P-deletion constructs were trans-
fected into BON cells and subsequently treated with IFN-K
(Fig. 2A). In untreated cells, the basal promoter activity was
doubled by deletion of the mCgA fragment spanning 34.8 to
31.2 kb, suggesting the presence of (a) basal repressor ele-
ment(s) within this region (Fig. 2A). Further deletion of
mCgA 5P-£anking DNA down to 3100 bp only modestly
in£uenced the basal promoter activity, whereas the loss of
an additional 39 bp (mCgA100-Luc versus mCgA61-Luc) re-
sulted in a dramatic reduction of basal mCgA promoter ac-
tivity (Fig. 2A). The inhibitory e¡ect of IFN-K on the basal
activity of the mCgA promoter was essentially not in£uenced
by deletion of mCgA 5P-£anking DNA from 34.8 kb down to
3100 bp (Fig. 2A). A further loss of 5P-£anking (mCgA61-
Luc construct) blunted the IFN-K e¡ect, suggesting the pres-
ence of the IFN-K-sensitive region of the mCgA promoter
between 3100 bp and 361 bp. Using the same set of
mCgA-Luc 5P-deletion constructs under conditions of PMA
stimulation, deletion down to 3100 bp of mCgA 5P-£anking
DNA had no e¡ect on the stimulatory action of PMA (Fig.
2B). Further 5P-deletion down to 361 bp resulted in a com-
plete loss of PMA-stimulated mCgA transcriptional activity as
well as IFN-K-dependent mCgA inhibition (Fig. 2B). Interest-
ingly, the basal activity of the mCgA61-Luc construct, which
lacks the proximal CRE site, did not show IFN-K-sensitivity
(Fig. 2B). These data indicate that basal as well as PMA- and
IFN-K-responsiveness of the mCgA promoter map to the
proximal mCgA core promoter region.
3.3. The mCgA-CRE mediates IFN-K-sensitivity of the mCgA
promoter
Previous studies revealed that a proximal core promoter
region of the mCgA gene located between 393 and 362 bp
is crucial for basal and stimulated promoter activity [11,12].
To determine the role of this region for the e¡ect of IFN-K,
we used a construct in which the sequence 393 to 362 bp is
joined to the heterologous, enhancerless viral TK promoter
(mCgA-93/-62-TK-Luc). We found that IFN-K inhibited the
activity of this construct with an identical potency and e⁄cacy
compared to the 5P-deletion constructs, suggesting that this
element is conferring mCgA IFN-K-responsiveness (Fig. 3A).
Fig. 1. IFN-K inhibits basal and PKC-stimulated mCgA promoter
activity. A: BON cells were transiently transfected with 1 Wg/well of
the mCgA4.8kb-Luc construct and treated with increasing concen-
trations of IFN-K (10^1000 IU/ml) for 24 h. B: BON cells were
transiently co-transfected with 1 Wg/well of each mCgA4.8kb-Luc
and a PKC-K expression construct. After pre-treatment with IFN-K
for 24 h, stimulation with PMA was performed for an additional 12
h. Cells were harvested and lysates were analyzed for Luc activity.
Luc activity is expressed as the fold increase of untreated controls
and values represent the mean þ S.E.M. of four experiments. Aster-
isks (*) indicate statistically signi¢cant inhibition compared to un-
treated controls (P6 0.001).
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Since the mCgA-CRE located at 371 to 364 bp has been
shown to be essential for basal and stimulated mCgA pro-
moter activity in neuroendocrine cells, we evaluated the role
of this element using mCgA100-Luc-based constructs in which
di¡erent mutations of the CRE site were introduced. In addi-
tion, we investigated the ability of a single copy of the CRE to
confer IFN-K-sensitivity to the per se IFN-K-insensitive TK
promoter. Deletion of the CRE in the context of 100 bp of 5P-
£anking mCgA DNA (mutants M13, M15) resulted in a dra-
matic reduction of basal and PMA-stimulated activity (Fig.
3B). While the mutant CRE sequence M13 (AcatcaccA)
showed a reproducible but not statistically signi¢cant IFN-
K-sensitivity, the CRE mutation M15 (GaccaT) was com-
pletely IFN-K-insensitive (Fig. 3B). In contrast, conversion
of the mCgA-CRE into an ‘ideal’ CRE (mutant
M14 = CGTcATT) resulted in enhanced basal and PMA-
Fig. 2. 5P-Deletion analysis of the IFN-K-sensitive region of the
mCgA promoter. A: BON cells were transiently transfected with
mCgA 5P-deletion constructs of decreasing length and treated with
IFN-K (1000 IU/ml) for 24 h. B: The same experiment as described
under A was performed with subsequent stimulation with PMA for
12 h. Luc activity is expressed as the fold increase of untreated con-
trols and values represent the mean þ S.E.M. of four experiments.
Asterisks (*) indicate statistically signi¢cant inhibition compared to
PMA-treated controls (P6 0.001).
Fig. 3. The mCgA-CRE mediates IFN-K-sensitivity of the mCgA
promoter. A: BON cells were transiently transfected with the
mCgA-93/-62-Tk-Luc construct, which comprises the mCgA core
promoter region. B: BON cells were transfected with mCgA100-
Luc-based constructs in which three di¡erent mutations were intro-
duced into the sequence of the mCgA-CRE at 368 bp. In the mu-
tant CgA M14, the mCgA-CRE was converted to the ‘ideal’ CRE
sequence of the human somatostatin gene. Basepairs that match
with the original mCgA-CRE sequence are shown in capital letters,
mismatches in small letters. C: BON cells were transfected with var-
ious heterologous Tk-Luc promoter constructs comprising the
mCgA-CRE in the unaltered (CRE-Tk-Luc 235) or mutated form
(CRE-Tk-Luc 236 and CRE-Tk-Luc 237). Where indicated, treat-
ment with IFN-K (1000 IU/ml) and/or PMA (10 nM) was done as
described in Fig. 1. Luc activity is expressed as arbitrary RLU and
values represent the mean þ S.E.M. Asterisks (*) indicate statistically
signi¢cant inhibition compared to untreated controls.
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stimulated promoter activity, as well as a more pronounced
sensitivity to IFN-K. In addition, a single copy of the mCgA-
CRE ligated upstream of the enhancerless viral TK promoter
was able to confer IFN-K-sensitivity to the same extent as
observed with the longest 5P-deletion construct mCgA4.8kb-
Luc (Fig. 3C). Point mutation of the CRE at 368 (CRE-Tk-
Luc 236) resulted in a dramatic reduction of basal and PKC-
stimulated mCgA activity and a complete loss of IFN-K-sen-
sitivity. In contrast, conversion of the mCgA-CRE into an
‘ideal’ CRE motif corresponding to the CRE of the somato-
statin gene resulted in full IFN-K-responsiveness of the TK-
Luc construct (CRE-Tk-Luc 237).
3.4. IFN-K a¡ects the mCgA-CRE through interaction with
CREB and CBP
Since the CREB adapter molecule CBP/p300 has been
shown to play a crucial role for CREB-dependent transacti-
vation of target genes, we investigated the functional role of
CREB and CBP for the e¡ect of IFN-K on the mCgA-CRE.
We found that overexpression of pCREB potently enhanced
mCgA-CRE-dependent transactivation (35^45-fold induc-
tion), while IFN-K treatment inhibited this e¡ect of CREB
by approximately 50% (Fig. 4A). In addition, CBP overex-
pression dose-dependently stimulated the activity of the
mCgA-CRE in the TK-Luc system, demonstrating the func-
tional importance of CBP for mCgA-CRE-dependent trans-
activation in BON cells (Fig. 4B). Overexpression of CBP also
reverted the inhibitory e¡ect of IFN-K on basal and PMA-
dependent activity of the mCgA-CRE. In contrast, sequestra-
tion of CBP by overexpression of the viral oncoprotein E1A,
which also binds CBP directly, resulted in diminished mCgA-
CRE-dependent transactivation (Fig. 4C).
4. Discussion
Analysis of neuroendocrine tumor samples from IFN-K-
treated patients revealed diminished expression of CgA
mRNA, suggesting that the CgA gene represents a molecular
target for IFN-K [8]. Since the vesicular matrix protein CgA
in£uences crucial steps of neuroendocrine secretory processes,
inhibition of CgA expression could represent a potential
mechanism by which IFN-K a¡ects the secretory capacity of
neuroendocrine tumor cells [9,10]. To investigate a potential
interference of IFN-K with the molecular machinery control-
ling mCgA gene transcription, we analyzed the e¡ects of IFN-
K on the mCgA promoter in vitro. Since previous studies
revealed a crucial role of PKC-related signaling cascades in
regulated CgA gene expression in neuroendocrine cells, we
also investigated the in£uence of IFN-K on PKC-stimulated
regulation of the mCgA promoter [11^14].
In a recent study, we found that IFN-K treatment of BON
cells exerts enhanced phosphorylation of STAT1/-2 and stim-
ulation of IFN-stimulated response element (ISRE)-dependent
transactivation [18]. In addition, our current study demon-
strates that IFN-K treatment of BON cells inhibits the basal
and PKC-stimulated transcriptional activity of the mCgA
promoter. 5P-Deletion analysis combined with mutational
analysis of the proximal mCgA core promoter (393 to 362
bp) revealed that the CRE element located at 371 to 364 bp
is indispensable for basal and PKC-stimulated mCgA activity
in BON cells. These data are in accordance with previous
studies, in which the proximal CRE site was uncovered as a
crucial determinant of basal and neuroendocrine-speci¢c tran-
scriptional activity of the human and mCgA genes, which are
highly homologous in their promoter sequences [11^13]. Fur-
thermore, our studies revealed a critical role of the proximal
mCgA-CRE for transmission of IFN-K-sensitivity to the
Fig. 4. E¡ect of IFN-K on the mCgA-CRE is mediated through in-
teraction with CREB and CBP. BON cells were transiently trans-
fected with the CRE-Tk-Luc 235 construct, which contains a single
copy of the mCgA-CRE linked to the heterologous TK promoter.
(A) Co-transfections were performed with expression vectors for
CREB and the constitutively active K-subunit of PKA, (B) increas-
ing amounts of an expression vector for CBP, (C) constructs encod-
ing CBP, the viral oncoprotein E1A or a functional incompetent
E1A mutant (E1Amut). Where indicated, treatment with IFN-K
(1000 IU/ml) and/or PMA (10 nM) was done as described in Fig. 1.
Luc activity is expressed as the fold increase of untreated controls
and values represent the mean þ S.E.M. Asterisks (*) indicate statis-
tically signi¢cant inhibition compared to untreated controls.
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mCgA promoter. Mutation of this element largely diminished
basal and PKC-dependent mCgA promoter activity and also
resulted in a loss of IFN-K-sensitivity (Fig. 3B,C). In contrast,
a single copy of the mCgA-CRE was able to confer IFN-K-
sensitivity to the per se IFN-K-insensitive heterologous viral
TK promoter. Mutation of the mCgA-CRE at 371 to 364 bp
resulted in a loss of most of the intrinsic activity, PMA-re-
sponsiveness as well as IFN-K-sensitivity, further con¢rming
the importance of this element for regulation of the mCgA
promoter. The fact that IFN-K also inhibited the transcrip-
tional activity of the ‘ideal’ CRE of the somatostatin gene (5P-
TGACGTCA-3P) (mutant M14 in Fig. 3 and CRE-Tk-Luc in
Fig. 3C) supports the view that CRE-like sequences in general
can function as IFN-K-responsive elements. Interestingly, the
somatostatin gene CRE (5P-TGACGTCA-3P) displayed a
more pronounced transcriptional inhibition by IFN-K, dem-
onstrating that subtle di¡erences in the sequence of this ele-
ment can also enhance the e¡ectiveness of IFN-K on CRE-
regulated transcription.
Analysis of the transcription factor(s) binding to the prox-
imal CgA-CRE of the mCgA gene in neuroendocrine cell lines
identi¢ed the transcription factor CREB as the principal nu-
clear protein responsible for basal and stimulated control of
this element [11^16]. CREB belongs to the family of leucine-
zipper transcription factors and represents the predominant
nuclear protein binding to the CRE consensus sequence 5P-
TGACGTCA-3P present in the 5P-£anking region of a number
of genes, such as somatostatin, tyrosine hydroxylase, pro-en-
kephalin and VIP [9]. CREB-dependent transactivation is gen-
erally controlled through phosphorylation of the serine resi-
due at position 133 of the transcription factor [9,11^14]. In
addition, recent studies suggested a model in which CREB-
dependent transactivation of CREs is critically determined by
the availability of the co-activator protein CBP/p300, which
physically interacts with CREB at its transactivation domain
and links the transcription factor to the basic transcriptional
complex [20,21]. Furthermore, it has been demonstrated that
IFN-regulated JAK/STAT signaling cascades can interfere
with CBP-dependent gene regulation [20,21]. IFNs exert their
anti-viral and anti-proliferative e¡ects through activation of a
speci¢c set of genes termed IFN-stimulated genes (ISGs) [5].
Transactivation of these genes in response to IFN is initiated
by Janus kinase-dependent phosphorylation of the latent cy-
toplasmic transcription factor ISG factor 3 (ISGF3), which
binds to the ISRE [5,21]. Recent studies demonstrated that
CBP/p300 can be found in the ISGF3 complex and that it
can physically interact with STATs and that this interaction
is required for IFN-stimulated transactivation of target genes
[19^21]. In contrast, acquisition of cellular CBP by STATs has
been shown to interfere with expression of genes, whose trans-
activation depends on the availability of CBP/p300 [19].
To determine the role of the CREB and CBP for mCgA
gene transcription in BON cells, we overexpressed both pro-
teins in the presence of the mCgA-CRE-Tk-Luc construct,
which contains a single copy of the mCgA-CRE. Expression
of either protein resulted in a potent transactivation of the
mCgA-CRE, which could be inhibited by IFN-K treatment.
In addition, expression of the viral oncoprotein E1A, which
has been shown to act as a CBP ‘scavenger’ [20], reproduced
the e¡ect of IFN-K on the mCgA promoter. Finally, the in-
hibitory e¡ect of IFN-K on the mCgA-CRE was fully reverted
by overexpression of either CBP or CREB, suggesting the
functional involvement of both proteins in this context. These
data are in accordance with a recent investigation analyzing
the inhibitory e¡ect of IFN-Q on the macrophage scavenger
receptor (MSR) gene, whose transactivation is critically deter-
mined by a nuclear complex comprising CBP and AP-1 [19].
The molecular analysis of IFN-Q-dependent inhibition of the
MSR transactivation revealed that STAT1 competes with AP-
1 for acquisition of cellular CBP protein and that elevation of
cellular STAT1 levels resulted in diminished CBP levels and
inhibition of MSR gene transcription [19].
Taken together, our data strongly support a concept in
which IFN-K inhibits CgA gene transcription through inhib-
ition of the proximal CRE element, which is crucial for basal
and PKC-dependent expression of the gene. Furthermore, our
study indicates that the inhibitory e¡ect of IFN-K involves
interference with CREB/CBP-dependent transactivation of
this element. Inhibition of CgA gene transcription in neuro-
endocrine tumor cells by IFN-K treatment therefore represents
one potential molecular aspect underlying the bene¢cial e¡ect
of IFN-K on the hypersecretion syndrome associated with
neuroendocrine tumor disease.
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